Evidence map›Paper›PMID 36348601›Full record

ArticleThe Indian journal of medical research

Characteristics & outcomes of cancer patients with COVID-19: A multicentre retrospective study from India.

Akash Kumar, Saphalta Baghmar, Prashant Mehta, Priya Tiwari, Lalit Kumar, Sameer Bakhshi, Amit Agarwal, Ishaan Gupta, Anjan Trikha, Sushma Bhatnagar and 14 more

Open access · diamondAbstract readMulticenter Study
In one paragraph

Article in The Indian journal of medical research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 1 country.

Akash KumarDepartment of Medical Oncology, National Cancer Institute, New Delhi, India.
Saphalta BaghmarDepartment of Medical Oncology, BL Kapur Hospital, New Delhi, India.
Prashant MehtaDepartment of Medical Oncology/Hematology/BMT, Asian Institute of Medical Sciences, Gurugram, Haryana, India.
Priya TiwariDepartment of Medical Oncology, Artemis Hospital, Gurugram, Haryana, India.
Lalit KumarDepartment of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
Sameer BakhshiDepartment of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
Amit AgarwalDepartment of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
Ishaan GuptaDepartment of Medical Oncology/Hematology/BMT, Asian Institute of Medical Sciences, Gurugram, Haryana, India.
Anjan TrikhaDepartment of Anaesthesiology, Pain Medicine & Critical Care, All India Institute of Medical Sciences, New Delhi, India.
Sushma BhatnagarDepartment of Onco-Anaesthesia & Palliative Medicine, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
Ajay GogiaDepartment of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
Prabhat Singh MalikDepartment of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
Ranjit Kumar SahooDepartment of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
Sameer RastogiDepartment of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
Raja PramanikDepartment of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
Atul BatraDepartment of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
Deepam PushpamDepartment of Onco-Anaesthesia & Palliative Medicine, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
Chitresh K SharmaDepartment of Surgical Oncology, National Cancer Institute, New Delhi, India.
Vinod SharmaDepartment of Medical Oncology, National Cancer Institute, New Delhi, India.
Babita KatariaDepartment of Medical Oncology, National Cancer Institute, New Delhi, India.
Kapil GoyalDepartment of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
Shreyas SamagaDepartment of Biochemical Engineering & Biotechnology, Institute of Technology, New Delhi, India.
Sneha J BothraDepartment of Medical Oncology/Hematology/BMT, Asian Institute of Medical Sciences, Gurugram, Haryana, India.
Atul SharmaDepartment of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
Asian Institute of Medical Sciences · INNational Institute of Medical Statistics · INDR. B.R.A. Institute Rotary Cancer Hospital · INAll India Institute of Medical Sciences · INArtemis Hospitals · INBLK Super Speciality Hospital · INDelhi State Cancer Institute · INIndian Institute of Technology Delhi · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & objectives: High mortality has been observed in the cancer population affected with COVID-19 during this pandemic. We undertook this study to determine the characteristics and outcomes of cancer patients with COVID-19 and assessed the factors predicting outcome. Methods: Patients of all age groups with a proven history of malignancy and a recent diagnosis of SARS-CoV-2 infection based on nasal/nasopharyngeal reverse transcriptase (RT)-PCR tests were included. Demographic, clinical and laboratory variables were compared between survivors and non-survivors groups, with respect to observed mortality. Results: Between May 11 and August 10, 2020, 134 patients were included from the three centres and observed mortality was 17.1 per cent. The median age was 53 yr (interquartile range 39-61 yr) and thirty four patients (25%) were asymptomatic. Solid tumours accounted for 69.1 per cent and breast cancer was the most common tumour type (20%). One hundred and five patients (70.5%) had received chemotherapy within the past four weeks and 25 patients (19.3%) had neutropenia at presentation. On multivariate analysis, age [odds ratio (OR) 7.99 (95% confidence interval [CI] 1.18-54.00); P=0.033], haemoglobin [OR 6.28 (95% CI 1.07-37.04); P=0.042] neutrophil-lymphocyte ratio [OR 12.02 (95% CI 2.08-69.51); P=0.005] and baseline serum albumin [OR 18.52 (95% CI 2.80-122.27); P=0.002], were associated with higher mortality. Recent chemotherapy, haematological tumours type and baseline neutropenia did not affect the outcome. Interpretation & conclusions: Higher mortality in moderate and severe infections was associated with baseline organ dysfunction and elderly age. Significant proportion of patients were asymptomatic and might remain undetected.

Indexed as

COVID-19NeoplasmsNeutropeniaAgedHumansIndiaMiddle AgedRetrospective StudiesSARS-CoV-2CancerCOVID-19infectionmortalityoutcome

Identifiers

PMID36348601
PMCPMC9807197
OpenAlexW4308684161

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.